Seiji Wakao
JPMorgan Chase & Co, Research Division
Good afternoon. Welcome to the J.P. Morgan Healthcare Conference. I’m Seiji Wakao, Japan pharma analyst. And it’s my pleasure to introduce Okamura-san, CEO of Astellas, and welcome him to the conference. Please go ahead, Okamura-san.
Naoki Okamura
President, CEO & Director
Thank you, Wakao-san. Hello. Good afternoon, everybody. My name is Naoki Okamura. I’m President and Chief Executive Officer of Astellas Pharma, Inc. I’m excited to be back in the J.P. Morgan Healthcare Conference. I hope some of you know a little bit about Astellas, but probably there are someone who, for the first time, start engaging with us. So I would like to talk about where we are today, where we are going to be in the near, mid to long term and more importantly, how we get there. Actually, we feel strong confidence in our growth trajectory in the longer term, so that I would like to share some excitement as well as the momentum that we feel today.
So first of all, we have a very clear, simple vision, which is to turn innovative science into VALUE for patients. When we use this, all capital, VALUE, it is clearly defined among the people at Astellas, which is outcomes that truly matter to patients divided by the costs to the entire health care system. It’s not the cost to us. It’s about the health care system. Therefore, if we are to explore increasing value, that means we try to create better outcomes for the patients and try to help managing the health care costs as the entire
Read the full article here
